Generic Copaxone Looms; Teva Fights And Prepares For Next Chapter
This article was originally published in The Pink Sheet Daily
Executive Summary
An appeals court ruling on July 26 favoring a faster route to a generic Copaxone brings to the fore longstanding issues of what its regulatory path might look like and how Teva will cope with the erosion of its top product’s sales.
You may also be interested in...
Emerging Markets Earnings Roundup: Astra Zeneca and Teva (Part 6)
AstraZeneca reports 21% growth in China, representing $72 million of the $154 million sales increase in emerging markets; and Teva reports $1.47 billion loss due to at-risk launches.
Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent
Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.
Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden
Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.